Brief: Virios Therapeutics Announces Results From Mid-Stage Study Of Imc-1 In Fibromyalgia

Dogwood Therapeutics

19/09/2022 12:24

Sept 19 (Reuters) - Virios Therapeutics Inc  VIRI.O :
    * VIRIOS THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PHASE
2B
STUDY OF IMC-1 IN FIBROMYALGIA
    * VIRIOS THERAPEUTICS INC - FORTRESS STUDY DID NOT ACHIEVE
STATISTICAL SIGNIFICANCE ON PRESPECIFIED PRIMARY EFFICACY
ENDPOINT
    * VIRIOS THERAPEUTICS INC - IMC-1 WAS WELL-TOLERATED
OVERALL, WITH
ONLY 4.6% OF IMC-1 TREATED PATIENTS DROPPING OUT DUE TO ADVERSE
EVENTS
    * VIRIOS THERAPEUTICS INC - ANALYSIS OF DATA SUGGESTS A
BIFURCATION OF RESPONSE BASED ON TIMING OF PATIENT ENROLLMENT IN
FORTRESS TRIAL.
    * VIRIOS THERAPEUTICS INC - OVERALL DISCONTINUATIONS WERE
18.5% IN
IMC-1 TREATED GROUP VERSUS 23% IN PLACEBO TREATED GROUP
    * VIRIOS THERAPEUTICS INC - NO ADVERSE EVENT CATEGORY IN
IMC-1
GROUP EXCEEDED A 4% RATE WITH EXCEPTION OF COVID-19 INFECTION
    * VIRIOS - BELIEVE INTERPLAY BETWEEN DIFFERENT COVID-19
STRAINS &
HERPES VIRUS ACTIVATION MAY BE CONTRIBUTING TO DIFFERENTIAL
RESPONSE IN PATIENTS ENROLLED IN 2021 VERSUS 2022

Source text for Eikon:  ID:nBw3jpN2ga 
Further company coverage:  VIRI.O 

 ((Reuters.Briefs@thomsonreuters.com;))